Novartis in hot water again over alleged kickbacks, revealing new DoJ probe related to Entresto
Novartis’ Entresto has proven a blockbuster drug since its approval in 2015, netting $924 million in sales this past quarter alone, representing a 46% gain from last year’s period. But the US government is calling the company’s sales practices into question, demanding info dating back years in a newly revealed probe.
The Department of Justice is seeking documents as far back as 2016 related to the marketing, pricing and payments to doctors for Entresto, Novartis revealed in its third quarter regulatory filing. Per the biopharma’s account, DoJ initiated the probe — known formally as a Civil Investigative Demand — this past September.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.